<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088409</url>
  </required_header>
  <id_info>
    <org_study_id>16277</org_study_id>
    <secondary_id>I4V-MC-JAHW</secondary_id>
    <secondary_id>2019-000119-10</secondary_id>
    <nct_id>NCT04088409</nct_id>
  </id_info>
  <brief_title>A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis</brief_title>
  <official_title>An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug baricitinib given orally is safe and&#xD;
      effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis&#xD;
      or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years&#xD;
      old.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">December 3, 2027</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>Week 24</time_frame>
    <description>Response is defined according to the Standardization of Uveitis Nomenclature (SUN) criteria as a 2-step decrease in the level of inflammation (anterior chamber cells) or decrease to zero through week 24, in the eye most severely affected at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SUN Grade of Cells in the Anterior Chamber in the Most Severely Affected Eye</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from Baseline in SUN Grade of Cells in the Anterior Chamber in the Most Severely Affected Eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SUN Grade of Cells in the Anterior Chamber in the Less Severely Affected Eye (If Applicable)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from Baseline in SUN Grade of Cells in the Anterior Chamber in the Less Severely Affected Eye (If Applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders in Participants with Bilateral Uveitis Disease at Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>Response is defined according to the SUN criteria as a 2-step decrease in the level of anterior chamber cells in the most severely affected eye at baseline (or both eyes if the inflammation grade is the same in both eyes) and a 1-step decrease in the level of anterior chamber cells in the less severely affected eye at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Visual Acuity Measured by Age-Appropriate Logarithm of the Minimum Angle of Resolution (LogMAR) Test</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from Baseline in Visual Acuity Measured by Age-Appropriate LogMAR Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Vitreous Haze</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from Baseline in Vitreous Haze</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Grade of Flare in the Anterior Chamber</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from Baseline in Grade of Flare in the Anterior Chamber</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Inactive Anterior Uveitis (using SUN Definition)</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of Participants with Inactive Anterior Uveitis (using SUN Definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Inactive Anterior Uveitis Disease (Using SUN Definition)</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>Time to Inactive Anterior Uveitis Disease (Using SUN Definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who are Able to Taper Concomitant Topical Corticosteroids to &lt;2 Drops Per Day</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of Participants who are Able to Taper Concomitant Topical Corticosteroids to &lt;2 Drops Per Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Response</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <description>Response is defined by a 2-step decrease in the level of inflammation (anterior chamber cells) or decrease to zero in the most severely affected eye at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PediACR30 Response Rate (For Participants with JIA-U)</measure>
    <time_frame>Week 24</time_frame>
    <description>PediACR30 Response Rate (For Participants with JIA-U)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Overall Uveitis-Related Disability</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from Baseline in Overall Uveitis-Related Disability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Baricitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab given subcutaneously (SC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Baricitinib</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have a diagnosis of JIA-U or chronic anterior antinuclear antibody&#xD;
             (ANA) positive uveitis without systemic features.&#xD;
&#xD;
          -  Participants must have active anterior uveitis, defined as cellular infiltrate in the&#xD;
             anterior chamber of SUN criteria grade ≥1+ at screening and randomization, despite&#xD;
             prior treatment with adequate doses of topical steroid therapy and methotrexate (MTX).&#xD;
&#xD;
          -  Participants must have an inadequate response or intolerance to MTX.&#xD;
&#xD;
          -  Participants must be on a stable dose of corticosteroid eye drops for at least 2 weeks&#xD;
             prior to screening with a maximum of 4 drops/day/eye at screening.&#xD;
&#xD;
          -  Participants and their partners of child bearing potential must agree to use 2&#xD;
             effective methods of contraception for the duration of the study and for at least 1&#xD;
             week following the last dose of investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have a history or presence of any autoimmune inflammatory&#xD;
             condition other than JIA, such as Crohn's disease or ulcerative colitis.&#xD;
&#xD;
          -  Participants must not have any contraindications to adalimumab.&#xD;
&#xD;
               -  Exception: Participants who are biologic disease-modifying antirheumatic drug&#xD;
                  (bDMARD) inadequate response or intolerance with a contraindication to adalimumab&#xD;
                  may be enrolled, as they will be assigned to baricitinib.&#xD;
&#xD;
          -  Participants must not have increased intraocular pressure ≥25 millimeters of mercury&#xD;
             (mm Hg) or that required treatment, including increases in medications, surgery, or&#xD;
             hospitalization, within 4 weeks prior to baseline that, in the opinion of the&#xD;
             investigator, would pose an unacceptable risk to the participant.&#xD;
&#xD;
          -  Participants must not have had intraocular surgery within the 3 months prior to&#xD;
             screening (such as for cataract(s), glaucoma or vitrectomy).&#xD;
&#xD;
          -  Participants must not have a current or recent (&lt;4 weeks prior to baseline) infection.&#xD;
&#xD;
          -  Participants must not have a positive test for hepatitis B virus (HBV) at screening.&#xD;
&#xD;
          -  Participants must not have evidence of active tuberculosis (TB) or untreated latent&#xD;
             TB.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33466686868</phone>
    </contact>
    <investigator>
      <last_name>Tu-Anh TRAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <state>Rhône-Alpes</state>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>330427856131</phone>
    </contact>
    <investigator>
      <last_name>Alexandre BELOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33145213246</phone>
    </contact>
    <investigator>
      <last_name>Isabelle Kone Paut</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GH Necker - Enfants Malades</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33144494828</phone>
    </contact>
    <investigator>
      <last_name>Pierre Quartier Dit Maire</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers - Hopital Jean Bernard</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033145213247</phone>
    </contact>
    <investigator>
      <last_name>Elisabeth Gervais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Sankt Augustin</name>
      <address>
        <city>Saint Augustin</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00492241249201</phone>
    </contact>
    <investigator>
      <last_name>Gerd Horneff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>004930940114510</phone>
    </contact>
    <investigator>
      <last_name>Ralf Trauzeddel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4930450666176</phone>
    </contact>
    <investigator>
      <last_name>Kirsten Minden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamburger Zentrum für Kinder und Jugendrheumatologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00494020923697</phone>
    </contact>
    <investigator>
      <last_name>Ivan Foeldvari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Gaslini - Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3901056362916</phone>
    </contact>
    <investigator>
      <last_name>Roberta Caorsi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>390390255031</phone>
    </contact>
    <investigator>
      <last_name>Giovanni Filocamo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>393297973141</phone>
    </contact>
    <investigator>
      <last_name>Gabriele Simonini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34936009733</phone>
    </contact>
    <investigator>
      <last_name>Jordi Antón López</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>915035900529</phone>
    </contact>
    <investigator>
      <last_name>Daniel Clemente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9172770002526</phone>
    </contact>
    <investigator>
      <last_name>Sara Murias Loza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>961244792</phone>
    </contact>
    <investigator>
      <last_name>Inmaculada Calvo Penades</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>Bristol, City Of</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>01173420149</phone>
    </contact>
    <investigator>
      <last_name>Athimalaipet V Vaidyanathan Ramanan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge Clinical Research Facility</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>441223348577</phone>
    </contact>
    <investigator>
      <last_name>Kate Armon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L14 5AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>01512284811</phone>
    </contact>
    <investigator>
      <last_name>Gavin Cleary</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>442381204829</phone>
    </contact>
    <investigator>
      <last_name>Theresa Alice Leahy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <state>N'castle-upon-tyne</state>
        <zip>NE14LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>01912825318</phone>
    </contact>
    <investigator>
      <last_name>Sharmila Jandial</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital For Children NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>02078297899</phone>
    </contact>
    <investigator>
      <last_name>Sandrine Lacassagne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>441142262305</phone>
    </contact>
    <investigator>
      <last_name>Daniel Philip Hawley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/5MwLoOOn4GIPFAxy1iilv6</url>
    <description>A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

